These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21589801)

  • 1. In vitro controlled release of colon targeted mesalamine from compritol ATO 888 based matrix tablets using factorial design.
    Patel JK; Patel NV; Shah SH
    Res Pharm Sci; 2009 Jul; 4(2):63-75. PubMed ID: 21589801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
    Li FQ; Hu JH; Deng JX; Su H; Xu S; Liu JY
    Int J Pharm; 2006 Nov; 324(2):152-7. PubMed ID: 16837152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HPMC - E15 LV premium polymer on release profile and compression characteristics of chitosan/ pectin colon targeted mesalamine matrix tablets and in vitro study on effect of pH impact on the drug release profile.
    Newton AM; Lakshmanan P
    Recent Pat Drug Deliv Formul; 2014 Apr; 8(1):46-62. PubMed ID: 24597626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets.
    Roberts M; Vellucci D; Mostafa S; Miolane C; Marchaud D
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1068-76. PubMed ID: 22149472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Box-Behnken experimental design in the development of pectin-compritol ATO 888 compression coated colon targeted drug delivery of mesalamine.
    Patel NV; Patel JK; Shah SH
    Acta Pharm; 2010 Mar; 60(1):39-54. PubMed ID: 20228040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of Sustained Release Tablet with Minimized Usage of Glyceryl Behenate Using Post-Heating Method.
    Kang C; Lee JH; Kim DW; Lee BJ; Park JB
    AAPS PharmSciTech; 2018 Oct; 19(7):3067-3075. PubMed ID: 30094721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride.
    Gambhire MN; Ambade KW; Kurmi SD; Kadam VJ; Jadhav KR
    AAPS PharmSciTech; 2007 Sep; 8(3):E73. PubMed ID: 17915823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot-melt coating technology. I. Influence of Compritol 888 Ato and granule size on theophylline release.
    Faham A; Prinderre P; Farah N; Eichler KD; Kalantzis G; Joachim J
    Drug Dev Ind Pharm; 2000 Feb; 26(2):167-76. PubMed ID: 10697753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of acyclovir oral tablets based on gastroretention technology: factorial design analysis and physicochemical characterization studies.
    El Gamal SS; Naggar VF; Allam AN
    Drug Dev Ind Pharm; 2011 Jul; 37(7):855-67. PubMed ID: 21401342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals.
    Aburahma MH; Badr-Eldin SM
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1865-83. PubMed ID: 25152197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and In Vitro and In Vivo Evaluation of Lipid-Based Terbutaline Sulphate Bi-layer Tablets for Once-Daily Administration.
    Hashem FM; Nasr M; Fathy G; Ismail A
    AAPS PharmSciTech; 2016 Jun; 17(3):727-34. PubMed ID: 26335420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the lubricant performance of Compritol HD5 ATO and Compritol 888 ATO: effect of polyethylene glycol behenate on lubricant capacity.
    N'Diaye A; Jannin V; Bérard V; Andrès C; Pourcelot Y
    Int J Pharm; 2003 Mar; 254(2):263-9. PubMed ID: 12623202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing a wet granulation process to obtain high-dose sustained-release tablets with Compritol 888 ATO.
    Rosiaux Y; Girard JM; Desvignes F; Miolane C; Marchaud D
    Drug Dev Ind Pharm; 2015; 41(10):1738-44. PubMed ID: 25652358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation Development and In-vitro/Ex-vivo Evaluation for a Polysaccharide-based Colon Targeted Matrix Tablet.
    Shaikh M; Desai N; Momin M; Bhatt LK
    Curr Drug Deliv; 2021; 18(10):1563-1573. PubMed ID: 34238183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterization of Compritol 888 ATO matrix tablets for the sustained release of diclofenac sodium.
    Roberts M; Pulcini L; Mostafa S; Cuppok-Rosiaux Y; Marchaud D
    Pharm Dev Technol; 2015 Jun; 20(4):507-12. PubMed ID: 24354893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic evaluation of the effect of sintering on Compritol 888 ATO matrices.
    Rao M; Ranpise A; Borate S; Thanki K
    AAPS PharmSciTech; 2009; 10(2):355-60. PubMed ID: 19333763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate.
    Obaidat AA; Obaidat RM
    Eur J Pharm Biopharm; 2001 Sep; 52(2):231-5. PubMed ID: 11522491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel stimuli-synchronized alloy-treated matrix for space-defined gastrointestinal delivery of mesalamine in the Large White pig model.
    Bawa P; Choonara YE; du Toit LC; Kumar P; Ndesendo VM; Meyer LC; Pillay V
    J Control Release; 2013 Mar; 166(3):234-45. PubMed ID: 23274950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction.
    Jannin V; Rosiaux Y; Doucet J
    J Control Release; 2015 Jan; 197():158-64. PubMed ID: 25445699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
    Perez MA; Ghaly ES; Marti A
    P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.